Clover Health Investments, Corp.
CLOV
$3.65
$0.1855.35%
| Weiss Ratings | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.14 | |||
| Price History | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.83% | |||
| 30-Day Total Return | -17.72% | |||
| 60-Day Total Return | 17.20% | |||
| 90-Day Total Return | -11.53% | |||
| Year to Date Total Return | 16.45% | |||
| 1-Year Total Return | 402.76% | |||
| 2-Year Total Return | 293.50% | |||
| 3-Year Total Return | 37.03% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -28.95% | |||
| 52-Week Low % Change | 470.96% | |||
| Price | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.87 | |||
| 52-Week Low Price | $0.61 | |||
| 52-Week Low Price (Date) | Apr 22, 2024 | |||
| 52-Week High Price (Date) | Jan 24, 2025 | |||
| Valuation | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.77B | |||
| Enterprise Value | 1.57B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.10 | |||
| Earnings Per Share Growth | -78.55% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.24 | |||
| Price/Book (Q) | 5.11 | |||
| Enterprise Value/Revenue (TTM) | 1.15 | |||
| Price | $3.65 | |||
| Enterprise Value/EBITDA (TTM) | -35.28 | |||
| Enterprise Value/EBIT | -34.25 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 491.87M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 201 432 2133 | |||
| Address | 3401 Mallory Lane Franklin, TN 37067 | |||
| Website | www.cloverhealth.com/en/ | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -3.35% | |||
| Profit Margin | -3.13% | |||
| Management Effectiveness | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -4.99% | |||
| Return on Equity | -- | |||
| Income Statement | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.34B | |||
| Total Revenue (TTM) | 1.37B | |||
| Revenue Per Share | $2.79 | |||
| Gross Profit (TTM) | 364.34M | |||
| EBITDA (TTM) | -44.60M | |||
| EBIT (TTM) | -45.93M | |||
| Net Income (TTM) | -43.01M | |||
| Net Income Avl. to Common (TTM) | -43.01M | |||
| Total Revenue Growth (Q YOY) | 9.28% | |||
| Earnings Growth (Q YOY) | 68.38% | |||
| EPS Diluted (TTM) | -0.10 | |||
| EPS Diluted Growth (Q YOY) | 68.83% | |||
| Balance Sheet | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 221.56M | |||
| Cash Per Share (Q) | $0.45 | |||
| Total Current Assets (Q) | 343.12M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 341.14M | |||
| Current Ratio (Q) | 1.607 | |||
| Book Value Per Share (Q) | $0.68 | |||
| Total Assets (Q) | 580.74M | |||
| Total Current Liabilities (Q) | 213.52M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 239.60M | |||
| Total Common Equity (Q) | 341.14M | |||
| Cash Flow | CLOV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 565.00K | |||
| Cash from Financing (TTM) | -17.36M | |||
| Net Change in Cash (TTM) | 18.05M | |||
| Levered Free Cash Flow (TTM) | 195.99M | |||
| Cash from Operations (TTM) | 34.85M | |||
